CTI BioPharma (United States)

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis

John Mascarenhas, Ronald Hoffman, Moshe Talpaz et al. · JAMA Oncology · 2018 · 358 citations · Full text

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

Ruben A. Mesa, Alessandro M. Vannucchi, Adam J. Mead et al. · The Lancet Haematology · 2017 · 300 citations · Full text

Hematological Malignancy, Oncology, Pacritinib Versus +9

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor

Jack W. Singer, Suliman Al‐Fayoumi, Haiching Ma et al. · Journal of Experimental Pharmacology · 2016 · 119 citations · Full text

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

Rami S. Komrokji, John F. Seymour, Andrew W. Roberts et al. · Blood · 2015 · 117 citations · Full text

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

Srđan Verstovšek, Olatoyosi Odenike, Jack W. Singer et al. · Journal of Hematology & Oncology · 2016 · 88 citations · Full text